Introduction: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on renal
outcomes in patients with chronic kidney disease (CKD) were initially demonstrated in …

Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes
mellitus and the leading cause of end-stage kidney disease. The standard treatments for …

Background: The objective of this systematic review was to evaluate the efficacy and safety
profiles of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for treatment of diabetes …

Introduction After stage 3 CKD, the risk of adverse cardiovascular events increased
significantly. Therefore, we performed a meta-analysis to investigate the cardiovascular …

Aims The overall effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients
with advanced chronic kidney disease (CKD)(estimated glomerular filtration rate (eGFR), 15 …

Millions of human deaths occur annually due to chronic kidney disease, caused by diabetic
kidney disease (DKD). Despite having effective drugs controlling the hyperglycemia and …

Background: To compare the effects of empagliflozin and linagliptin use on kidney outcomes
of type 2 diabetes mellitus (T2DM) patients in a real-world setting. Methods: The study …

New drugs were recently developed to treat hyperglycemia in patients with type 2 diabetes
mellitus (T2D). However, metformin remains the first-line anti-diabetic agent because of its …

Background and aims Outcome trials using sodium glucose cotransporter type 2 inhibitors
have consistently shown their potential to preserve kidney function in diabetic and …

Objective To determine the efficacy and safety of Astragalus combined with renin-
angiotensin-aldosterone system (RAAS) blockers in treating stage III diabetic nephropathy …